Success Metrics

Clinical Success Rate
88.1%

Based on 104 completed trials

Completion Rate
88%(104/118)
Active Trials
10(6%)
Results Posted
59%(61 trials)
Terminated
14(9%)

Phase Distribution

Ph phase_3
27
17%
Ph phase_4
43
28%
Ph phase_1
17
11%
Ph not_applicable
17
11%
Ph phase_2
48
31%
Ph early_phase_1
3
2%

Phase Distribution

20

Early Stage

48

Mid Stage

70

Late Stage

Phase Distribution155 total trials
Early Phase 1First-in-human
3(1.9%)
Phase 1Safety & dosage
17(11.0%)
Phase 2Efficacy & side effects
48(31.0%)
Phase 3Large-scale testing
27(17.4%)
Phase 4Post-market surveillance
43(27.7%)
N/ANon-phased studies
17(11.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.2%

104 of 122 finished

Non-Completion Rate

14.8%

18 ended early

Currently Active

10

trials recruiting

Total Trials

155

all time

Status Distribution
Active(15)
Completed(104)
Terminated(18)
Other(18)

Detailed Status

Completed104
unknown18
Terminated14
Recruiting7
Not yet recruiting5
Withdrawn4

Development Timeline

Analytics

Development Status

Total Trials
155
Active
10
Success Rate
88.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (1.9%)
Phase 117 (11.0%)
Phase 248 (31.0%)
Phase 327 (17.4%)
Phase 443 (27.7%)
N/A17 (11.0%)

Trials by Status

not_yet_recruiting53%
recruiting75%
withdrawn43%
active_not_recruiting32%
completed10467%
terminated149%
unknown1812%

Recent Activity

Clinical Trials (155)

Showing 20 of 155 trialsScroll for more
NCT06727773Phase 2

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

Recruiting
NCT02288000Phase 1

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

Terminated
NCT07560878Early Phase 1

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

Recruiting
NCT03527472Phase 2

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Completed
NCT03703856Phase 4

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

Completed
NCT05013892Phase 2

NTS-WBRT in Brain Metastases

Recruiting
NCT07531940Phase 1

Escalating Doses of Memantine in Down Syndrome (MEDS-123)

Not Yet Recruiting
NCT03550391Phase 3

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
NCT07248228Phase 2

Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

Not Yet Recruiting
NCT07504198Phase 2

Neuroprotection of Memantine and Rosuvastatin

Not Yet Recruiting
NCT07470606Phase 2

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

Not Yet Recruiting
NCT07417670Phase 4

Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease

Completed
NCT04857983Phase 2

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

Completed
NCT05418049Phase 2

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

Active Not Recruiting
NCT05796752Phase 2

Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors

Active Not Recruiting
NCT00262470Phase 1

Treatment of Orthostatic Intolerance

Active Not Recruiting
NCT06041789Phase 2

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

Recruiting
NCT02466191Phase 4

Treatment of Pendular Nystagmus in OPT

Completed
NCT01744444Phase 2

Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis

Completed
NCT04588246Phase 3

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
155